Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Dasatinib (Primary) ; Nivolumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 21 Jan 2020 Status changed from active, no longer recruiting to discontinued.
- 16 Aug 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2021.
- 16 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.